Page 4 - Sanofi

Sanofi to reward shareholders with Rs 261 cr made from Ankleshwar unit sale

The sale will translate into average annual revenue loss of Rs 470 cr, which Sanofi plans to mitigate through renewed focus on core activities and brands

Sanofi: Strong domestic portfolio keeps Street positive amid pricing pain

Analysts at Elara Capital say the company's portfolio being skewed toward the high-growing chronic products, coupled with its leadership position in basal insulin, gives it an edge over its peers

Sanofi ends partnership with Lexicon to develop add-on pill for diabetes

Shares of Lexicon fell nearly 40% in extended trading

Sanofi partners Google to use AI, analytics tools for better treatments

The use of Google's tools for deep analytics -- organising large amounts of data to make insights -- will help it better understand key diseases and patient outcomes to make further improvements

Sanofi: Strong anti-diabetic range, exports may prove healthy for investors

Despite the cut in forward estimates due to pressure on margins, earnings are expected to grow by more than 20 per cent annually over the next two years

Bitter pill to swallow: Margin worries ahead for Sanofi

Price cuts, a higher share of exports have led to a revision of margin estimates

Sanofi to pay Regeneron $462 million in revised immuno-oncology deal

Sanofi will pay Regeneron $462 million representing the balance of payments due under their original deal

Sanofi India: High-margin diabetic products and exports to drive profits

The top seven brands have together grown at 21 per cent annually and now account for 46 per cent of Sanofi's sales

Growth recovery on the cards for Sanofi

The year 2016 may have not been good for Sanofi India, andMarch 2017 quarter numbers did not impress either. But, the company's fortunesare seen changing for the better.The company follows a January-December financial year. While2016 performance was impacted because of the new drug pricing policy anddemonetisation, the March 2017 quarter numbers were weighed down by prolongedeffect of the note ban and lower exports revenue. Sanofi said lower exportvolumes and rupee appreciation versus the euro had an adverse impact on itssales and profitability for the quarter.These events have weighed on the stock, which at ~4,210 isnot much higher than its 52-week lows of ~4,005. However, with analystsconfident of a rebound in company performance, the correction offers a goodopportunity to buy the stock. Sanofi is well known for its brands such as Combiflam,Lantus, Avil, etc, besides its vaccines and diabetes portfolio. For itsflagship brands, the month of March itself has instigated confidence. Of

For Sanofi, better days loom ahead

The year 2016 was challenging for Sanofi India, the drug maker known for its brands such as Combiflam, vaccines and diabetes portfolio. While the drug price control impacted the company's performance in the early part of CY2016 (follows January-December accounting year), note ban weight on its December quarter numbers. These have led to its stock price remaining under pressure. But, as the impact fades out, analysts expect the company to report a strong rebound in revenue, profitability and thereby stock price, which is why they are now bullish on Sanofi. Post the company reported its December quarter and financial year performance on Monday, analysts have strong buy recommendation on the stock. The expectations stem from the fact that despite pressure due to price control, volume growth in key brands is expected to be strong and will drive overall revenue. Also, launch of new product line extensions and exports of insulin pens will mean further gains. Analysts such as Ranjit Kapadia .

Sanofi sues Glenmark, Torrent over sclerosis drug

Sanofi had received letters from Torrent and Glenmark, with a notice of their new drug applications

Sanofi Q2 net up 33% at Rs 85 crore

Total income rises to Rs 608 cr

New Sanofi vaccine facility starts commercial production

Unit will initially produce pentavalent and cholera vaccines, will be also registered for hepatitis B and tetanus shots

Sanofi scrip falls marginally a day after Combiflam recall

The Drugs Controller General of India found Sanofi's popular painkiller drug to be of sub-standard quality twice in the past three months

Sanofi recalls batches of Combiflam after regulator alert

DCGI had issued an alert twice, saying drug was sub-standard, as its disintegration in the blood stream was delayed